Navigation Links
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant immunosuppressive medications, the mainstay of treatments for noninfectious uveitis. This is the second mid-stage trial for basiliximab run by Cerimon, which began a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007.

"The initiation of this proof-of-concept study is part of our overall strategy to seek additional indications for already marketed drugs in areas with significant unmet medical needs," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "In noninfectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often associated with oral or topical corticosteroids while maintaining effective control of their inflammation."

Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases including noninfectious uveitis. In February 2006, the Company licensed basiliximab from Novartis Pharma AG for the treatment of Inflammatory Bowel Disease (IBD) and initiated a Phase IIb clinical study for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis the following year. In December 2007, Cerimon entered into an agreement with Novartis to conduct a proof-of-concept study for basiliximab for the treatment of noninfectious uveitis.

About Noninfectious Uveitis

Uveitis is an inflammation of the internal structures of the eye. Uveitis can be described by the underlying condition that causes it: autoimmune (noninfectious), bacterial, viral, parasitic and eye trauma, and by the part of the eye that it affects: anterior, intermediate, posterior and panuveitis. Noninfectious uveitis affects approximately two hundred forty thousand people worldwide and can lead to complications, such as glaucoma, cataract and total vision loss. Current treatments include topical and oral corticosteroids, steroidal implants and immunosuppressive drugs; however, these generally have limited success and can lead to adverse events.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians to further improve the lives of their patients.

Cerimon currently has two drugs in clinical development. The Company's autoimmune program has two development programs. The lead program is a Phase IIb study in which Simulect(R) (basiliximab) is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for noninfectious uveitis in a Phase II study. Cerimon's lead asset in its pain portfolio is the Company's topical formulations of diclofenac. The Company is in mid-stage clinical testing with its topical diclofenac products.

The Company continues to seek additional assets to add to its development pipeline and is financed by the premier investors MPM, Nomura Phase4 Ventures and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at .

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
3. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... While it’s often important to take certain medications during the ... Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL ... it eliminates the need to turn on a light when taking medication during the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):